Redhill Biopharma Ltd. (RDHL) Receives New Coverage from Analysts at UBS AG

UBS AG began coverage on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in a research report report published on Wednesday. The brokerage issued a reduce rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Redhill Biopharma from a hold rating to a sell rating in a report on Saturday, July 29th. Roth Capital set a $27.00 target price on shares of Redhill Biopharma and gave the company a buy rating in a report on Monday, July 31st. HC Wainwright set a $33.00 target price on shares of Redhill Biopharma and gave the company a buy rating in a report on Thursday, June 15th. Finally, FBR & Co reaffirmed a buy rating on shares of Redhill Biopharma in a report on Friday, June 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $23.69.

Redhill Biopharma (NASDAQ RDHL) traded down 0.47% during midday trading on Wednesday, reaching $8.53. The company had a trading volume of 8,307 shares. The stock’s 50 day moving average price is $8.85 and its 200-day moving average price is $9.40. The firm’s market capitalization is $146.40 million. Redhill Biopharma has a one year low of $8.16 and a one year high of $15.35.

Redhill Biopharma (NASDAQ:RDHL) last issued its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). The firm had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.34 million. On average, equities research analysts anticipate that Redhill Biopharma will post ($2.36) earnings per share for the current year.

WARNING: “Redhill Biopharma Ltd. (RDHL) Receives New Coverage from Analysts at UBS AG” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/14/redhill-biopharma-ltd-rdhl-receives-new-coverage-from-analysts-at-ubs-ag.html.

A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its holdings in Redhill Biopharma by 144.1% in the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after acquiring an additional 36,600 shares during the period. D.A. Davidson & CO. raised its holdings in Redhill Biopharma by 10.0% in the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after acquiring an additional 4,000 shares during the period. Jane Street Group LLC bought a new position in Redhill Biopharma in the 1st quarter valued at about $276,000. Family Management Corp raised its holdings in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock valued at $222,000 after acquiring an additional 8,750 shares during the period. Finally, Oppenheimer & Co. Inc. raised its holdings in Redhill Biopharma by 10.8% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock valued at $220,000 after acquiring an additional 2,500 shares during the period. 10.99% of the stock is currently owned by hedge funds and other institutional investors.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply